Merck buys Rigontec for up to €464mm
Merck & Co. Inc. will pay €115mm ($136.9mm) up front to acquire Rigontec GMBH, a privately held biotech developing immuno-oncology therapies targeting the retinoic acid-inducible gene I (RIG-I) pathway in the innate immune system. The deal also includes up to €349mm in development, regulatory, and commercialization earn-outs.
- Antisense, Oligonucleotides
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com